The HER-2/neu oncogene has >25 HLA epitopes, yet only one FVB/N mouse CD8 + T-cell epitope has been mapped to date. This epitope has been termed the immunodominant epitope for the FVB/N mouse, but we propose that the vaccination strategy determines the dominance of epitopes. Using a series of overlapping peptides, we have mapped another CD8 + T-cell epitope that emerges in the FVB/N mouse following vaccination with Listeria monocytogenes-based vaccines that express fragments of HER-2/neu. Following the identification of this novel H-2K q -restricted epitope, we sought to compare the T-cell response to this epitope with the previously identified PDSLRDLSVF epitope. This newly identified epitope and the previously identified epitope lie within fragments contained in different vaccines, the PDSLRDLSVF epitope in Lm-LLO-EC2 and the newly identified PYNYLSTEV epitope in Lm-LLO-EC1; thus, it has been possible to compare the responses of these epitopes independent of any competing response between the epitopes. CTL analysis of individual peptide-pulsed target cells and intracellular cytokine stain for IFN-; produced by splenocytes from Lm-LLO-EC1 compared with Lm-LLO-EC2 vaccinated FVB/N mice shows that there is no difference between the responses generated to either of these epitopes. We also show that the avidity of the CD8 + T cells for either of these epitopes is similar based on the concentration of peptide necessary to mediate similar levels of lysis of target cells. In addition, HER-2/neu DNA vaccination followed by CTL analysis further showed that both of these peptides can emerge as epitopes. (Cancer Res 2006; 66(15): 7748-57) 
Introduction
The CD8 + T-cell population generated against a specific tumor antigen is a vital component of a potent antitumor immune response (1) (2) (3) (4) (5) . Several tumor-associated antigens have been identified, and the specific immune responses that can be generated by targeting these antigens is being studied in both humans and in mouse models of cancer (3, (6) (7) (8) . Determining the epitopes against which CTL responses can be generated is an important factor in characterizing antitumor immune responses because it allows for the direct measurement of antitumor immunity against a single specificity.
A frequently targeted tumor-associated antigen is HER-2/neu, which is a 185-kDa transmembrane glycoprotein and a member of the epidermal growth factor family of receptors (9) (10) (11) . It is overexpressed in 15% to 40% of all breast cancers and contributes to the tumor phenotype, which makes it a good target for immunotherapy (12, 13) . Specific anti-HER-2/neu CD8 + T-cell (14) responses have been detected in patients with HER-2/neu overexpressing breast cancers, and several epitopes against which these responses are directed have been mapped. The epitopes identified in the human HER-2/neu span the entire protein (15) (16) (17) (18) (19) (20) . However, although antitumor CD8 + T cells are generated by some patients, along with any antibodies or CD4 + T cells produced, they are not enough to overcome the effects of tolerance and eradicate the tumors (14, 21, 22) .
Several strategies have been developed to target HER-2/neu as a method of treating breast cancers that overexpress this oncogene. These include whole-cell vaccines, vaccinia vaccines, and DNA vaccines among others (23) (24) (25) (26) . Our lab has previously described a series of Listeria monocytogenes vaccines expressing fragments of HER-2/neu, all of which are capable of inducing stasis in the growth of established implanted tumors in wild-type (wt) FVB mice (5) . Each of these five vaccines can also generate anti-HER-2/neuspecific CD8 + T-cell responses, which are a key component of their antitumor efficacy. Due to its ability to exist within the host cell, primarily antigen-presenting cells (APC), L. monocytogenes can generate both a specific CD4 + and CD8 + T-cell response to secreted antigens (27) (28) (29) . Through fusion of the tumor antigen to a truncated, nonhemolytic form of listeriolysin O (LLO), secretion of the tumor antigen is ensured (30) . Fusion to LLO is also thought to target the fusion protein for proteasomal degradation, which allows for the foreign protein to be efficiently targeted to the MHC class I processing pathway (31, 32) .
Previously, in the FVB/N mouse, only one CD8 + T-cell epitope had been mapped, the H2-D q -restricted PDSLRDLSVF epitope, which has been called the immunodominant HER-2/neu MHC class I epitope for this mouse (33, 34) . Based on our previous antitumor and CTL data, we concluded that there must be more than one FVB/N T-cell epitope present for the rat HER-2/neu protein (5) . The previously mapped HER-2/neu epitope was determined to be the immunodominant epitope in the FVB/N mouse because this was the only epitope identified upon the generation of specific T-cell clones following vaccination with whole-cell tumor vaccines transduced with granulocyte macrophage colony-stimulating factor (GM-CSF) and vaccinia vaccines expressing HER-2/neu (34) . The demonstration that other regions of HER-2/neu contain CTL epitopes challenges this conclusion (5) . Dominance may be determined by the type of vaccination, the dose of antigen given, and the time that the response is studied (35) (36) (37) (38) . It is also greatly determined by the potential T-cell repertoire that is available for generation of antigen-specific CD8 + T cells (39) (40) (41) (42) . Depending on the route and type of vaccine, different T-cell pools may be primed and expanded. Out of all these factors, this study looks primarily at the effect of the type of vaccination on the generation of the antigen-specific CD8 + T-cell response and the strength of this response against two different epitopes.
Here, we identify another rat HER-2/neu CD8 + T-cell epitope for the FVB/N mouse that is in a different region of the protein than the previously mapped epitope. Furthermore, we go on to characterize the immune response that can be generated targeting either of these epitopes to determine how the CD8 + T-cell response differs. Our findings show that the ''dominance'' of epitopes is determined by many factors, including the method of generating the antigenspecific CD8 + T cells. Given the interest in using HER-2/neu for human cancer immunotherapies, including peptide-based therapies, a complete knowledge of the epitopes in this animal model for HER-2/neu overexpressing cancers will allow for the better design and preclinical testing of therapies directed to this antigen.
Materials and Methods
L. monocytogenes vaccines. The L. monocytogenes-based vaccines for HER-2/neu used in this study were described previously (5) . A similarly constructed L. monocytogenes-based vaccine for NY-ESO-1 was kindly provided by Dr. Paulo Maciag and was used as a control for antigen specificity in some experiments. Bacteria were grown in brain heart infusion medium (BD, Sparks, MD) with 50 Ag/mL chloramphenicol and frozen in 1 mL aliquots at À80jC. To inject mice, the vaccines were thawed and washed twice with sterile PBS before being resuspended in PBS.
Mice. Six-to 8-week-old female FVB/N mice were purchased from Charles River Laboratories (Wilmington, MA). Animals were cared for and used in accordance with protocols approved by the Animal Care and Use Committee of the University of Pennsylvania (Philadelphia, PA).
Cell lines. The NT-2 tumor cell line was developed from a spontaneously occurring mammary tumor in an FVB/N HER-2/neu transgenic mouse (43) . These cells constitutively express low levels of rat HER-2/neu and were used as a feeder cell line as a source of antigen for the restimulation of splenocytes in CTL assays. NT-2 cells were grown in RPMI 1640 supplemented with 20% FCS, 10.2 mL HEPES, 2 mmol/L L-glutamine, 100 Amol/L nonessential amino acids, 1 mmol/L sodium pyruvate, 50 units/mL penicillin G, 50 Ag/mL streptomycin, 20 Ag/mL insulin, and 2 Ag/mL gentamicin. Several different target cell lines were used for the CTL assays. NIH 3T3 cells are a mouse fibroblast line and 3T3-neu cells were made by transducing these cells with the full-length rat HER-2/neu as previously described (33) . The NIH 3T3 cells (3T3-wt) were cultured in DMEM supplemented with 10% FCS, 2 mmol/L L-glutamine, 100 Amol/L nonessential amino acids, 1 mmol/L sodium pyruvate, 50 units/mL penicillin G, and 50 Ag/mL streptomycin. Additionally, the 3T3-neu cell line was supplemented with 1 mg/mL G418. The 16-3-1N and 3-83P hybridomas (American Type Culture Collection, Manassas, VA) were used to produce antibodies used as blocking antibodies in CTL analyses. Both of these cell lines produce antibodies that are IgG2a. Cells were cultured in DMEM supplemented with 10 mmol/L HEPES, 2 mmol/L L-glutamine, solution I (1 mmol/L oxalacetic acid, 20 units/mL insulin, 0.5 mmol/L sodium pyruvate), 100 Amol/L nonessential amino acids, 10% NCTC 135, and 12% FCS. All cells were grown at 37jC with 5% CO 2 .
DNA vaccines. Escherichia coli cells containing the DNA vaccine plasmids of pcDNA3.1-neu and pcDNA3.1-LLO-neu were generated as described previously (5) . pcDNA3.1-LLO-E7 was used as a negative control for the HER-2/neu DNA vaccines. Cultures were grown in Luria-Bertani supplemented with ampicillan at 37jC. Plasmids containing the antigens were isolated using a DNA plasmid purification maxi prep kit (Qiagen Sciences, Germantown, MD).
Peptides. Nine-and 10-mers were synthesized as lyophilized peptides by EZBiolab (Westfield, IN). All peptides were reconstituted in water at a 1 mg/ mL concentration.
Flow cytometry. q antibody conjugated to FITC. Samples were run on a Beckman Coulter FACSCalibur, and the data were analyzed using FlowJo (Treestar, Ashland, OR). 51 Cr release assays. Six-to 8-week-old mice were vaccinated i.p. with 0.1 LD 50 of Lm-LLO-EC1, Lm-LLO-EC2, or 200 AL PBS. Nine days later, splenocytes were harvested and set up to be restimulated. Briefly, whole splenocytes were plated in 24-well plates at a ratio of 10:1 with irradiated NT-2 (20,000 rad) tumor cells and 20 units/mL interleukin-2 (IL-2; Roche, Indianapolis, IN). Four days later, splenocytes were harvested and used in a standard 51 Cr release assay. Target cells were labeled with chromium and then cultured with splenocytes at the effector-to-target (E:T) ratios of 200:1, 100:1, 50:1, and 25:1, in triplicate for 4 hours. Before labeling the target cells with chromium in peptide-loaded assays, cells were pulsed for 1 hour at 37jC with 1 Ag/mL of the appropriate peptide. When blocking antibodies were used to block binding of the peptide to the MHC, target cells were treated with antibodies before loading with peptide. The percent specific lysis was determined as [(experimental counts per minute À spontaneous counts per minutes) / (total counts per minute À spontaneous counts per minute)] Â 100.
Intracellular cytokine stain. Mice were vaccinated with either PBS, Lm-LLO-NYESO1, Lm-LLO-EC1, and Lm-LLO-EC2 to test the Listeria-based vaccines, or PBS, DNA-LLO-E7, DNA-LLO-neu, and DNA-LLO-EC1 to test the ability of the DNA vaccines to stimulate the production of IFN-g. Spleens were harvested, and splenocytes were isolated 9 days after vaccination and cultured with the appropriate stimulus, including GolgiPlug (BD, Franklin Lakes, NJ) to prevent secretion of IFN-g, in 96-well plates. Anti-CD3/CD28 stimulation was used as a positive control, and three stimulation groups consisting of the EC1, EC2, and IC1 peptides at a 1 Ag/mL concentration were used during an 8-hour in vitro stimulation of the splenocytes. Cells were then surface stained with CD8 (53-6.7, FITC conjugated), CD11b PerCP, and CD62L (Mel-14, APC conjugated; BD, Franklin Lakes, NJ). Cells were then fixed and permeabilized using a cytofix/ cytoperm solution (BD, Franklin Lakes, NJ) and then stained with IFN-g PE before fluorescence-activated cell sorting (FACS) analysis on a FACSCalibur. FACS data were then analyzed using Flowjo software (Treestar).
Statistics. The Student's t test was used for all statistical analyses. Significance is noted when P < 0.05.
Results
Identification of a novel HER-2/neu epitope. The immunodominant CD8 + T-cell epitope for rat HER-2/neu in the FVB/N mouse was been identified as PDSLRDLSVF (33) . Based on our previous tumor regression and CTL data, we had identified regions of HER-2/neu, which contain unidentified CD8 + T-cell epitopes (5) and further narrowed these regions down to 20 mers. We found more than one CD8 + T-cell epitope exists in the EC1 region from amino acids 20 to 326, including an epitope in the 20-mer spanning amino acids 291 to 310 (data not shown). At this point, further identification of the epitope was frustrated by the fact that there are no predictive algorithms for the FVB/N mouse, which is on the H-2 q background. Hansen et al. has shown that the H-2D q and H-2L q genes are very similar to the H-2 d genes (44, 45) . Using the ''d'' haplotype as a guide, we analyzed the sequence of the 20-mer with the Rankpep algorithm (http://mif.dfci.harvard.edu/Tools/ rankpep.html) and identified 9-and 10-mers that were likely to bind to d and thus to q. The peptides that were predicted by the algorithm: VTTCPYNYL, TFGASCVTT, TFGASCVTTC, and PYNYL-STEV, were used for CTL analyses. By pulsing these peptides individually onto 3T3-wt target cells, we identified one 9-mer that would target cells for lysis by CD8 + T cells (Fig. 1D ). The response is specific to the PYNYLSTEV peptide as seen by the complete lack of response to any of the other three peptides (Fig. 1A-C) .
CTL responses to both the old and the new epitopes are similar. Upon identification of this novel HER-2/neu epitope, we sought to determine whether this new EC1 epitope is as potent in stimulating a CTL response as the previously identified immunodominant epitope. We did a side-by-side CTL analysis by pulsing the target cells with either the previously identified EC2 or the new EC1 epitope and using splenocytes from mice vaccinated with either Lm-LLO-EC1 or Lm-LLO-EC2 as effector cells (Fig. 2) . There is no lysis when the peptide used as a target does not fall into the region of HER-2/neu that the vaccine spans; thus, the lysis seen is specific for the particular peptide used. At an E:T ratio of 200:1, we observed about 50% lysis of the EC1 peptide-loaded target cells with the Lm-LLO-EC1 immune splenocytes ( Fig. 2A) , whereas with the EC2 peptide and the Lm-LLO-EC2 splenocytes we observed about 40% lysis (Fig. 2B ). There is no significant difference between the lysis seen for the two peptides at all E:T ratios. Based on this analysis, at a peptide concentration of 1 Ag/mL, the known EC2 epitope is not immunodominant to the new EC1 epitope, PYNYLSTEV.
DNA vaccines show the ability to target both epitopes at one time. One main difference between the L. monocytogenes-based vaccines and vaccination approaches where full-length HER-2/neu has been used is the fact that the Listeria-based vaccines use fragments of HER-2/neu. Although we have shown that this factor does not seem to significantly increase the antitumor effect of these vaccines, it is possible that the use of fragments increases the variety of epitopes that can be targeted through vaccination (5) . Using DNA vaccines that we have previously described, we attempted to determine if we could generate a CTL response against both of these epitopes through vaccination with full-length HER-2/neu. CD8 + T-cell responses can be generated targeting both of these epitopes using an LLO-fused full-length HER-2/neu DNA vaccine, although the response to the EC2 epitope is greater than the response to the EC1 epitope ( Table 1) .
Production of IFN-; from splenocytes from Listeria-based vaccine-treated mice is similar for cells reactive to the PDSLRDLSVF epitope and to the PYNYLSTEV epitope, but differences in responsiveness emerge with splenocytes from DNA-vaccinated mice. Mice were vaccinated with Lm-LLO-EC1, Lm-LLO-EC2, or PBS, and splenocytes were harvested and analyzed for the production of IFN-g after stimulation with the EC1 and EC2 peptides. This stimulation, as seen through the production of IFN-g, is specific for the vaccine given and the corresponding peptide (Fig. 3A) . Regardless of the stimulus used during the 8-hour in vitro culture, the splenocytes from the PBS-treated (data not shown) or Lm-LLO-NY-ESO-1-vaccinated mice did not respond with any significant production of IFN-g (Fig. 3A) . Stimulation with an irrelevant HER-2/neu peptide resulted in a negligible level of IFN-g production for all the vaccination groups (data not shown). Following stimulation with the EC2 peptide, there was an increased amount of production of IFN-g from Lm-LLO-EC2-vaccinated mice but not from Lm-LLO-EC1-vaccinated mice (Fig. 3A, bottom) , and conversely, the EC1 peptide stimulation led to increased IFN-g production from Lm-LLO-EC1-vaccinated mice but not from Lm-LLO-EC2-vaccinated mice (Fig. 3A, top) . Furthermore, the level of IFN-g production observed by the Lm-LLO-EC2 mice in response to the EC2 peptide and the Lm-LLO-EC1 mice in response to the EC1 peptide were very similar. Mice were also vaccinated with PBS, DNA-LLO-E7, DNA-LLO-neu, and DNA-LLO-EC1 to observe the extent of IFN-g production stimulated by the DNA vaccines. Similar to the Listeria-based vaccines, the PBS-treated (data not shown) and the DNA-LLO-E7-vaccinated mice had a negligible level of IFN-g production by the immune splenocytes regardless of which peptide was used as a stimulus (Fig. 3B) . Again, stimulation with an irrelevant HER-2/neu peptide resulted in no IFN-g production by any of the DNA vaccine groups (data not shown). Stimulation with the EC2 peptide resulted in the production of IFN-g by splenocytes from DNA-LLO-neu-treated mice but not from the DNA-LLO-EC1-treated mice (Fig. 3B, bottom) , and stimulation with the EC1 peptide resulted in the production of IFN-g from the DNA-LLO-EC1 and DNA-LLO-neu mice (Fig. 3B, top) . Unlike the Listeria-based vaccines, where a similar level of IFN-g production was seen from the Lm-LLO-EC1 splenocytes stimulated with the EC1 peptide and the Lm-LLO-EC2 splenocytes stimulated with the EC2 peptide, a greater level of IFN-g production was seen upon stimulation with the EC2 peptide than with the EC1 peptide with the splenocytes from DNA-LLO-neu-treated mice; 5.91% of activated CD8 + T cells from DNA-LLO-EC1-vaccinated mice produced IFN-g when stimulated with the EC1 peptide. When mice are treated with DNA-LLO-neu, only 2.25% produced IFN-g in response to the EC1 peptide, but this level rose to 7.4% in response to the EC2 peptide (Fig. 3B ). This shows that where similar levels of effector activity, as measured by IFN-g production, can be stimulated by Listeria-based vaccines to fragments of HER-2/neu, when the vaccine contains both of these epitopes, a greater level of the effector response seems to be directed to the EC2 epitope.
Avidity of the CD8 + T cells induced by the Lm-LLO-EC1 and Lm-LLO-EC2 vaccines are similar in response to the two peptides with both Listeria-based and DNA-based vaccines. At a very high peptide concentration of 1 Ag/mL (Fig. 2) , the lytic responses targeting the two peptides are very similar. However, it was possible that differences in the responses of the different peptide-specific CD8 + T cells could become apparent when the concentration of peptide pulsed onto the target cells is decreased. This will serve to show differences in the avidities of the T cells (46) (47) (48) . A high concentration of peptide will be necessary to stimulate low-avidity T cells, whereas high-avidity T cells will be stimulated at high and low concentrations (48) . Dominant epitopes are likely to be able to stimulate low avidity cells, whereas less dominant epitopes may not be capable of activating cytotoxic cells that have a low avidity for the peptide. Concentrations ranging from 1 Ag/mL down to 100 pg/mL were used to target cells to elicit a lytic response from effector splenocytes to determine whether the previously identified immunodominant epitope can stimulate lower avidity cells than the new EC1 epitope. At both a high E:T ratio ( Fig. 4A and B) and a lower E:T ratio (data not shown), both of the peptides stimulate similar levels of lysis when the CD8 + NOTE: Similar levels of lysis are seen against the PYNYLSTEV epitope from both the pcDNA LLO-neu-and the pcDNA LLO-EC1-vaccinated mice. There is no lysis seen of the PDSLRDLSVF epitope from pcDNA LLO-EC1 splenocytes as this epitope is not contained within this vaccine. Percent specific lysis was calculated by subtracting background lysis levels from PBS-vaccinated mice for the lysis for each vaccine. Specific lysis by the PBS vaccinated mice was 5% to 6%. *Denote levels of specific lysis above background (P < 0.05). T cells are primed by the Listeria-based vaccines. Very high levels of lysis can be seen at the low nanogram concentration of either peptides. Lower levels of lysis of target cells is seen with splenocytes from DNA-LLO-EC1-vaccinated mice versus the DNA-LLO-neu-vaccinated mice ( Fig. 4C and D) . The response towards the EC2 peptide primed by the DNA-LLO-neu vaccine is higher even at a nanogram concentration of peptide than that for the EC1 peptide, although a response can be seen against the EC1 peptide. At both high and low E:T ratios, T cells induced by Lm-LLO-EC1, Lm-LLO-EC2, DNA-LLO-neu, and DNA-LLO-EC1 are antigen specific as evidenced by the lack of lysis to 3T3-wt cells (data not shown). PYNYLSTEV epitope is restricted to H-2K q . The previously identified PDSLRDLSVF epitope has been shown to be H-2D q restricted (33) . We next sought to identify the MHC class I restriction of the new PYNYLSTEV peptide, which had been identified by Rankpep as a K d binder. To do this, we pulsed both the peptides individually onto L cells that had been transfected with either the H-2D q or the H-2L q genes (45) . As expected, when the PDSLRDLSVF peptide is pulsed onto L-D q cells, there is killing of target cells, but this is not seen with peptide-pulsed L-L q cells (data not shown). When the EC1 peptide is pulsed onto either of these cell lines, there is no killing of the target cells (data not shown). Based on this, we believe that the EC1 PYNYLSTEV peptide is actually restricted to H-2K q , as this MHC class I molecule is present in the FVB/N mouse and the 3T3 target cell line but is absent on the L-D q or -L q cells. As there is no cell line that expresses only H-2K q , we studied the binding of the EC1 peptide to this MHC through the use of an H-2K q -specific blocking antibody and as a control a nonspecific antibody (Fig. 5A-D ). First, we tested target cells to confirm that the antibody specifically binds to H-2K q and not to other ''q'' restricted MHC molecules by FACS analysis. Cells were treated with FITClabeled H-2K q or biotinylated H-2L q /D q , in the presence or absence of 16-3-1N or 3-83P. The 16-3-1N antibody specifically blocks H-2K q ( Fig. 5A and B) , whereas the 3-83P antibody does not block H-2K q , L q , L q , or D q ( Fig. 5C and D) and can thus be used as a negative control for the 16-3-1N antibody. We then tested the ability of 16-3-1N to block lysis of target cells pulsed with the EC1 epitope by splenocytes from Lm-LLO-EC1-treated mice. When target cells were treated with 16-3-1N before loading with peptide, splenocytes from Lm-LLO-EC1-treated mice showed no cytolytic activity against target cells (Fig. 5E) . However, target cells treated with 3-83P and pulsed with the EC1 peptide were killed by splenocytes from Lm-LLO-EC1-treated mice (Fig. 5F ). Based on these data, we conclude that the PYNYLSTEV peptide is restricted to H-2K q . These data also suggest that the peptide-binding motifs of K d and K q are similar.
Both the PDSLRDLSVF and the PYNYLSTEV epitopes are naturally processed and presented by tumor cells. Although Figure 3 . Activation and production of IFN-g is specific for cells stimulated by a vaccine containing a particular epitope, but the levels of stimulation differ based on the vaccine strategy employed. A, mice were vaccinated with PBS, Lm-LLO-NY-ESO-1, Lm-LLO-EC1, and Lm-LLO-EC2. Top, splenocytes were stimulated with 1 Ag/mL of the EC1 PYNYLSTEV peptide. Bottom, splenocytes were stimulated with 1 Ag/mL of the EC2 PDSLRDLSVF peptide. B, mice were vaccinated with PBS, DNA LLO-E7, DNA LLO-EC1, and DNA LLO-neu. Top, splenocytes were stimulated with 1 Ag/mL of the EC1 peptide. Bottom, splenocytes were stimulated with 1 Ag/mL of the EC2 peptide.
unlikely, it is possible that the new EC1 epitope was not previously identified due to the fact that it is an epitope that is not naturally processed and presented by tumor cells. We tested for this possibility using a CTL assay where the in vitro stimulus was changed from irradiated tumor cells to peptide, and the target cells were tumor cells (3T3-wt, 3T3-neu, and NT-2 cells). When no peptide is provided as a stimulus, as expected, there is no lysis of any of the target cells from the PBS, Lm-LLO-EC1, or the Lm-LLO-EC2 splenocytes (Fig. 6A, D, and G) . Use of the PYNYLSTEV peptide as a stimulus results in no lysis of 3T3-wt cells from any of the vaccine groups, but the Lm-LLO-EC1 splenocytes are capable of killing both the 3T3-neu cells and the NT-2 cells (Fig. 6B, E, and H) . Similarly, stimulating the splenocytes using the PDSLRDLSVF peptide leads to no killing of 3T3-wt cells from any of the groups, but splenocytes from Lm-LLO-EC2 mice kill both the 3T3-neu and NT-2 cells (Fig. 6C, F, and I) . These results clearly show that both of these epitopes are naturally processed and presented by the NT-2 and 3T3-neu tumor cells and further, that the HER-2/neu peptides are similar in their ability to expand splenocytes to kill tumor cells expressing HER-2/neu.
Discussion
In this study, we have identified a novel rat HER-2/neu epitope in the FVB/N mouse revealed by L. monocytogenes-based vaccination. In addition, the previously mapped immunodominant epitope is not in actual fact ''dominant'' to this epitope, with this vaccination strategy. Our previous tumor regression and CTL analyses have indicated that there are multiple epitopes for rat HER-2/neu in the FVB/N mouse that have not yet been identified (5) . Additionally, there have been many CD8 + T-cell epitopes mapped for the human HER-2/neu, which are spread throughout the entire length of the HER-2/neu protein (8, 15-17, 19, 20, 44) .
The human and rat proteins are extremely similar to each other, with a >90% homology (49) . This information and our data led us to conclude that there were unmapped epitopes for rat HER-2/ neu in the FVB/N mouse.
To map other epitopes, we have continued with the mapping strategy that we had developed previously, which is to use CTL analysis as an indicator for the presence of a CD8 + T-cell epitope (5). Using overlapping 20-mers, we first narrowed down the areas of HER-2/neu containing an epitope and then used the Rankpep algorithm and estimates of peptide binding to H-2 d molecules to break these 20-mers into smaller peptides that are the correct length for MHC class I binding. The areas containing an epitope have been further mapped. H-2 d has previously been shown to have structural homology to H q (44, 45, 50) . The four peptides that were predicted for an EC1 20-mer were then used to identify a novel class I epitope for the FVB/N mouse, and a subsequent series of experiments were done to show that EC2 is not dominant with EC1 using our vaccine strategy.
One issue that arises in identifying CD8 + T-cell epitopes through CTL analyses is whether the new class I epitope arises by natural processing and presentation of HER-2/neu expressed in tumor cells. To generate CD8 + T cells for CTL analysis immune splenocytes were expanded ex vivo for 4 days before being used in the chromium release assay. In our assays, the source of antigen given to restimulate the antigen-specific T cells are wholeirradiated tumor cells. The APCs present in the culture of whole splenocytes takes up these dying tumor cells and processes and presents antigens to the T cells. This implies that the EC1 epitope is naturally processed by the APCs because CTL are generated that recognize it as well as the EC2 epitope. However, to confirm this, we expanded Lm-LLO-EC1 splenocytes ex vivo with the peptide and showed that the peptide-specific CTL could lyse tumor cells that express HER-2/neu. A and C, the target peptide is the EC1 PYNYLSTEV peptide. B and D, the target peptide is the EC2 PDSLRDLSVF peptide. *, P < 0.05, significant levels of lysis above background lysis.
Several factors are involved in determining the hierarchy of dominance of epitopes and if there is an immunodominant epitope in a system. This begins with antigen processing and then progresses to recognition by the T-cell of the peptide-MHC complex (35, 36, 38, 39, 41, 42, (51) (52) (53) . Involved in this is the T-cell repertoire that is present and capable of being amplified in response to vaccination with a particular tumor antigen. In the case of the epitope described here and the previously described epitope, there should be no difference in the basic T-cell repertoire that is capable of being amplified due to the fact that the same strain of mouse is used in both studies.
In a simple attempt to determine if the EC2 epitope is immunodominant to the EC1 epitope, we conducted CTL analysis along with intracellular cytokine production analysis for IFN-g, and based on these analyses, neither epitope seems dominant to the other (Figs. 2 and 3 ). There are several factors that do differ in how this epitope was defined versus the previous epitope that was defined by the Jaffee lab using irradiated whole 3T3 cells transduced with GM-CSF as a vaccine in addition to a vaccinia vaccine containing full-length HER-2/neu (23, 33) . They used T-cell clones derived from vaccinated mice and overlapping peptides in CTL analyses to determine the sequence of the EC2 epitope as PDSLRDLSVF. All of the T-cell clones generated, responded to this single peptide, which for this reason, was determined to be the immunodominant epitope for HER-2/neu in the FVB/N mouse (33) . To map the EC1 epitope in this article, we used L. monocytogenes-based vaccines containing fragments of HER-2/ neu. We did not use T-cell clones, but instead, we used a polyclonal primary T-cell pool in our CTL analyses to identify CD8 + T-cell epitopes.
It is possible that the different methods of generating an anti-HER-2/neu immune response could result in a very different pool of CD8 + T cells. Irradiated whole-cell vaccines administer a dose of antigen that is determined by the amount of neu expression by the 3T3 cells (33) . The vaccinia vaccine on the other hand could lead to the production of higher levels of antigen in APCs and potentially allow for a varied pool of responder CD8 + T cells to be generated. It is interesting to note therefore that T-cell clones with similar specificities were generated using both of these vaccination strategies. However, T-cell clones do not necessarily represent the responding T-cell pool. T-cell clones are stimulated and kept alive through the continual administration of IL-2 along with a source of antigen, which generally results in the generation of a clone that is selected through its ability to respond robustly by division to the given stimulus (54) . Clearly, this may not be the most highly responding, or more importantly, the only CD8 + T-cell capable of responding in vivo during an immune response. We have shown that there is a group of T cells within a polyclonal population with high avidity for the EC1 epitope. We believe that there are many other epitopes in HER-2/neu, which we are continuing to map, because all five of our Lm-HER-2/neu fragment vaccines generate CD8 + T cells that have potent antitumor activity (5). The DNA vaccines used in this study further support the idea that the vaccination strategy determines what epitopes emerge upon vaccination and the dominance of these epitopes (Table 1 ; Fig. 3B; ref. 55 ). pcDNA-LLO-neu induces both a CTL and IFN-g response targeting the novel PYNYLSTEV epitope, but the response to this epitope is much lower than the response to the previously defined PDSLRDLSVF epitope. This suggests that with other vaccine strategies epitopes could be undetectable, as seems to have been the case for the EC1 epitope with the strategies used by Erocolini et al. (33) . In the case of the Listeria-based vaccines that Figure 6 . The PYNYLSTEV and the PDSLRDLSVF epitopes are naturally processed and presented by tumor cells. Splenocytes from vaccinated mice were in vitro restimulated with no peptide (A, D , and G ), the PYNYLSTEV peptide (B, E, and H ), or the PDSLRDLSVF peptide (C, F , and I ). A to C, there was no killing of 3T3-wt target cells regardless of the stimulus used for restimulation. D and G, there was no killing of either the 3T3-neu or the NT-2 target cells when no peptide was used for the restimulation. E and H, when the PYNYLSTEV peptide is used for restimulation, only splenocytes from Lm-LLO-EC1-vaccinated mice are capable of killing either the 3T3-neu or the NT-2 target cells. F and I, only the Lm-LLO-EC2 splenocytes are capable of killing either the 3T3-neu or NT-2 tumor cells when restimulated with the PDSLRDLSVF peptide. Percent specific lysis was calculated as % = 100 Â[(experimental À spontaneous) / (total À spontaneous)]. *, P < 0.05, significance.
target these epitopes, we see no difference in the CTL response against these epitopes (Figs. 2-3 ). This could be because when stimulated simultaneously, the EC2 epitope is the immunodominant epitope, but taken side-by-side with individual vaccines, there is no dominance among these epitopes. Titrating the peptides down to look at the avidity of the CD8 + T cells shows that the same avidity T-cell can be activated targeting both the EC1 and the EC2 peptides. What differs though is the level of lysis that can be induced targeting either peptide, with a greater response directed towards the EC2 peptide (Fig. 4C and D) . Using Listeria, no difference is seen between either the avidity or the level of lysis directed towards either peptide. Based on this, it becomes clear that the vaccination strategy does indeed determine the dominance of CD8 + T-cell epitopes and not some inherent characteristic of the epitope itself.
When discussing dominance and the generation of CD8 + T cells capable of responding to different epitopes another consideration is the possible presence of CD4 + CD25 + regulatory T cells (56) . In the case of the whole-cell vaccinations and the vaccinia vaccines, it is possible that regulatory T cells are being induced, which are not being generated with this Listeria-based vaccine system. We have previously shown that our episomal based Listeria vaccines do not induce a significant production of regulatory T cells in contrast to other vaccine approaches (57, 58) . In the case of the DNA vaccines (Table 1) , whole-cell vaccines, and vaccinia vaccines, it may be that regulatory T cells prevent the response of CD8 + T cells that are specific for epitopes other than the PDSLRDLSVF epitope (34) .
